Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Neramexane (merz pharmaceuticals/forest laboratories).

Gerhard Rammes1, Anja Schierloh

  • 1Clinical Neuropharmacology, Max Planck Institute of Psychiatry, Kraepelinstrasse 2-10, 80804 Munich, Germany. rammes@mpipsykl.mpg.de

Idrugs : the Investigational Drugs Journal
|March 9, 2006
PubMed
Summary

Neramexane, an N-methyl-D-aspartate antagonist, is being developed for central nervous system disorders like Alzheimer's disease. It also shows potential for treating substance dependence and pain.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Neuron-tumor communication in solid tumors: from bona fide synapses to pseudo-synaptic neural interfaces.

Trends in cancer·2026
Same author

Corrigendum to 'Pridopidine stabilizes mushroom spines in mouse models of Alzheimer's disease by acting on the sigma-1 receptor' [Neurobiology of Disease Volume 124 April 2019 Pages 489-504].

Neurobiology of disease·2026
Same author

Correction: Shi et al. The Anaesthetics Isoflurane and Xenon Reverse the Synaptotoxic Effects of Aβ<sub>1-42</sub> on Megf10-Dependent Astrocytic Synapse Elimination and Spine Density in Ex Vivo Hippocampal Brain Slices. <i>Int. J. Mol. Sci.</i> 2023, <i>24</i>, 912.

International journal of molecular sciences·2025
Same author

Sensory neurons drive pancreatic cancer progression through glutamatergic neuron-cancer pseudo-synapses.

Cancer cell·2025
Same author

Non-rapid eye movement sleep and isoflurane-induced anesthesia show divergent subcortical connectivity patterns during transition phases in mice.

Sleep·2025
Same author

GAL-201 as a Promising Amyloid-β-Targeting Small-Molecule Approach for Alzheimer's Disease Treatment: Consistent Effects on Synaptic Plasticity, Behavior and Neuroinflammation.

International journal of molecular sciences·2025

Area of Science:

  • Neuropharmacology
  • Central Nervous System Disorders

Background:

  • Merz Pharmaceuticals and Forest Laboratories are investigating neramexane.
  • Neramexane is an oral N-methyl-D-aspartate (NMDA) antagonist.

Purpose of the Study:

  • To evaluate neramexane as a neuroprotective agent.
  • To explore its therapeutic potential in Alzheimer's disease.
  • To assess its efficacy in treating drug and alcohol dependence and pain.

Main Methods:

  • Pharmacological development of neramexane.
  • Clinical trials for central nervous system disorders.
  • Investigational studies for substance dependence and pain management.

Main Results:

  • Neramexane demonstrates potential as a neuroprotectant.
  • Investigational data suggests possible applications in Alzheimer's disease.
  • Preliminary findings indicate utility in managing dependence and pain.

Conclusions:

  • Neramexane is a promising therapeutic candidate for neurological conditions.
  • Further research is warranted for its application in addiction and pain management.

Related Experiment Videos